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ABSTRACT 1 
Background: HIV, hepatitis C virus (HCV), and alcohol-related diagnoses (ARD) independently 2 
contribute increased risk for all-cause hospitalization. We sought to determine annual medical 3 
intensive care unit (MICU) admission rates and relative risk of MICU admission between 1997 4 
and 2014 among people with and without HIV, HCV, and ARD, using data from the largest HIV 5 
and HCV care provider in the United States. 6 
Setting: Veterans Health Administration. 7 
Methods: Annual MICU admission rates were calculated among 155,550 patients in the 8 
Veterans Aging Cohort Study by HIV, HCV, and ARD status. Adjusted rate ratios (RR) and 95% 9 
confidence intervals (CI) were estimated with Poisson regression. Significance of trends in age-10 
adjusted admission rates were tested with generalized linear regression. Models were stratified 11 
by calendar period to identify shifts in MICU admission risk over time. 12 
Results: Compared to HIV-/HCV-/ARD- patients, relative risk for MICU admission decreased 13 
among HIV mono-infected patients from 61% (95% CI 1.56-1.65) in 1997-2009 to 21% (95% CI 14 
1.16-1.27) in 2010-2014, increased among HCV mono-infected patients from 22% (95% CI 15 
1.16-1.29) in 1997-2009 to 54% (95% CI 1.43-1.67) in 2010-2014, and remained consistent 16 
among patients with ARD only at 46% (95% CI 1.42-1.50). MICU admission rates decreased by 17 
48% among HCV-uninfected patients (p-trend<0.0001) but did not change among HCV+ 18 
patients (p-trend=0.34). 19 
Conclusion: HCV infection and ARD remain key contributors to MICU admission risk. The 20 
impact of each of these conditions could be mitigated with combination of treatment of HIV, 21 
HCV, and interventions targeting unhealthy alcohol use. 22 
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Introduction 1 
People with HIV infection are living longer on combination antiretroviral therapy (ART), 2 
but continue to experience excess risk for multiple chronic conditions compared to 3 
demographically similar HIV-uninfected individuals, including pulmonary,1 cardiovascular,2 and 4 
liver disease.3 Further, these chronic medical conditions associated with aging are major 5 
contributors to risk of all-cause hospitalization4 and mortality5 and may progress more rapidly in 6 
HIV-infected (HIV+) patients. Since ART became widely available, hospitalization rates among 7 
HIV+ patients have decreased4 while rates of medical intensive care unit (MICU) admissions 8 
have remained stable or even increased.6 9 
 10 
A growing percentage of MICU admissions among HIV+ patients are due to 11 
complications arising from hepatitis C virus (HCV) co-infection.7 HCV infection is more common 12 
in patients with HIV than their HIV-uninfected counterparts.8 Compared with HIV mono-infected 13 
patients, HCV co-infection is associated with approximately 50% increased risk of 14 
hospitalization, most often attributed to infection-related diagnoses.9 Although safe and effective 15 
treatments for HCV infection became widely available in the United States in 201410, the risk of 16 
MICU admission conferred by HCV infection before 2014 remains largely unknown.  17 
 18 
While effective treatments for HIV and HCV infection have led to improved health 19 
outcomes, common and potentially modifiable health behaviors, such as alcohol consumption, 20 
represent the next challenge.11 A previous study showed that one-third of MICU admissions 21 
were associated with heavy alcohol consumption.12 Alcohol-related diagnoses (ARD), including 22 
alcohol use disorder and other conditions caused by alcohol (e.g., alcoholic liver disease, 23 
alcoholic gastritis), are commonly associated with conditions that lead to MICU admission 24 
among HCV+ patients.13 ARD are also common among HIV+ patients14, and sequalae such as 25 
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physiologic injury15 and mortality16 occur at lower levels of alcohol exposure than among 1 
uninfected patients. Importantly, even low levels of alcohol use can aggravate deleterious 2 
effects of HIV and HCV infection on the liver.17 3 
 4 
As HIV has become a chronic medical condition, the growing relevance of HCV infection 5 
and ARD on MICU admission requires quantification as a first step toward identifying new 6 
targets for medical intervention. We used data from an observational cohort in the Veterans 7 
Health Administration (VA), the largest HIV and HCV care provider in the United States, and 8 
Medicare, the largest healthcare insurer in the United States, to calculate annual MICU 9 
admission rates and relative risk for MICU admission between 1997 and 2014 among people 10 
living with and without HIV, HCV, and ARD. 11 
 12 
Methods 13 
Study design and cohort 14 
We conducted a retrospective cohort study among patients in the Veterans Aging Cohort 15 
Study (VACS), which has been previously described.18 Briefly, VACS is a large observational 16 
cohort based on data from the national VA electronic health record system that includes all 17 
HIV+ patients in VA care (over 50,000 subjects) matched 1:2 with HIV-uninfected patients 18 
based on age, sex, race/ethnicity, and site of care. For this analysis, we calculated annual MICU 19 
admission rates among all VACS patients who were active in VA care (i.e., had at least one 20 
outpatient or inpatient visit) in each calendar year between 1997 and 2014. Baseline date was 21 
defined as the date of VACS enrollment, which is the first HIV diagnosis date within the VA for 22 
HIV+ patients or date of matching for HIV-uninfected controls. Patients were followed until their 23 
last VA visit date or death. HIV-uninfected controls (n=338) who seroconverted during follow-up 24 
were excluded. The development of VACS has been approved by the Institutional Review 25 
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Boards of the VA Connecticut Healthcare System and Yale University School of Medicine, was 1 
granted a waiver of informed consent, and deemed HIPAA compliant. 2 
 3 
MICU admission and principal diagnoses 4 
MICU admission data were extracted from national VA and Medicare databases. VA 5 
MICU admission was identified by inpatient bed section codes 12 or 13. Bed section code 12 6 
included cardiac ICU (CICU) admissions until 2008 when CICU was given a separate bed 7 
section code, 13. For the purposes of this analysis, MICU refers to both MICU and CICU 8 
admissions. Medicare MICU admissions were identified from MEDPAR data using MICU and 9 
CICU indicator variables. Admissions that resulted from a transfer from another unit were 10 
included in this analysis. For each MICU admission we obtained principal diagnosis for the 11 
hospitalization, according to International Classification of Diseases, Ninth Revision (ICD-9) 12 
code and categorized them as in previous studies4,7 (see Table, Supplemental Digital Content 13 
1). 14 
 15 
Exposure groups 16 
Eight exposure groups were created using all combinations of HIV, HCV, and ARD 17 
status. HIV status was determined as previously described in VACS.18 HCV infection was 18 
defined by positive HCV RNA during the study period. Time-updated ARD included validated 19 
ICD-9 codes for alcohol intoxication/ingestion, alcohol-induced mental disorders, alcohol 20 
dependence syndrome, alcoholic polyneuropathy/cardiomyopathy/gastritis, and alcohol-related 21 
liver diseases (see Table, Supplemental Digital Content 1).19 Patients were classified as ARD+ if 22 
in the previous year they had at least two outpatient encounters with an ARD; they remained 23 
ARD+ thereafter. 24 
 25 
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Covariates 1 
We extracted data on demographics including age, sex, and race/ethnicity. Age was 2 
categorized into 5-year age groups ensuring adequate numbers in each age and exposure 3 
group category when calculating age-adjusted, annual MICU admission rates. Common 4 
comorbid conditions were extracted using ICD-9 codes for psychiatric disorders, hypertension, 5 
drug use-related diagnoses, anemia, cardiovascular disease (CVD), diabetes, chronic 6 
obstructive pulmonary disorder (COPD), renal insufficiency, non-AIDS cancers, chronic hepatitis 7 
B infection, and liver diseases. Comorbidities were defined by one inpatient or two outpatient 8 
diagnostic codes (see Table, Supplemental Digital Content 1) and considered present at 9 
baseline if the diagnosis date occurred within one year before or six months after baseline date. 10 
We also extracted laboratory data, including CD4 cell count and FIB-4 (a composite measure of 11 
liver injury incorporating values for age, platelet count, AST, and ALT), and among HIV+ 12 
patients, pharmacy data to identify ART initiation. 13 
 14 
Statistical analyses 15 
We compared baseline demographic and clinical characteristics across the eight 16 
exposure groups using non-parametric Kruskal-Wallis tests for continuous measures and chi-17 
square (χ2) tests for categorical measures. We calculated annual MICU admission rates by 18 
dividing the total number of MICU admissions by the number of patients at risk in a given 19 
calendar year (i.e., having at least one inpatient or outpatient visit). Patients with multiple MICU 20 
admissions could only contribute one admission per calendar year of follow-up. We estimated 21 
age-adjusted MICU admission rates, as well as rate ratios (RR) with 95% confidence intervals 22 
(95% CI) for each HIV/ARD/HCV exposure group adjusted for baseline age, comorbidity (i.e., 23 
psychiatric disorders, hypertension, drug use-related diagnoses, diabetes, cardiovascular 24 
disease, anemia, chronic obstructive pulmonary disorder, non-AIDS cancers, renal insufficiency, 25 
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chronic hepatitis B, and liver diseases), and calendar year using Poisson regression. Covariates 1 
were selected based on a priori hypotheses informed by clinical relevance and because they 2 
represent potential confounders in the relationship between HIV, HCV, or ARD and risk of MICU 3 
admission, as well as availability of data. We tested for trends in annual MICU admission rates 4 
using generalized linear regression models. We estimated the individual and combined 5 
associations of HIV, HCV, and ARD with risk of MICU admission in three ways: 1) comparing 6 
HIV/HCV/ARD groups to the HIV-/HCV-/ARD- group, 2) comparing HIV/ARD groups stratified 7 
by HCV infection, and 3) comparing HCV/ARD groups stratified by HIV infection. We also 8 
stratified the study period into two eras to assess differential impacts of each exposure between 9 
1997-2009 and 2010-2014. We selected these specific time periods to highlight findings from 10 
the most recent five years of follow-up that would be most relevant to current patients. Statistical 11 
analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA). Statistical 12 
significance was defined as p<0.05. 13 
 14 
Results 15 
Cohort characteristics 16 
Between 1997 and 2014, 155,550 patients met study inclusion criteria (contributing 17 
1,525,267 person-years); 32% were HIV+, 13% were HCV+, and 30% had an ARD during 18 
follow-up. Median baseline age was 47 years (interquartile range [IQR] 40-54 years) (Table 1). 19 
Most patients were male (97%), 47% were black, and 40% were white. While 42% of the 20 
sample had no baseline comorbidity, 29% had only one and the remaining 28% had two or 21 
more. The most common comorbidities at baseline were psychiatric disorders (27%), 22 
hypertension (27%), drug use-related diagnoses (14%), diabetes (12%), and CVD (6%).  23 
 24 
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Each of the eight exposure groups based on HIV, HCV, and ARD had ≥3,500 patients, 1 
the largest being the group with none of the exposures (n=69,511). ARDs were more common 2 
in HCV+ patients (58%) and HIV+ patients (30%) than patients with neither HCV nor HIV (27%) 3 
(p<0.0001). Overall mortality was 2.9 deaths per 100 person-years of observation. Patients with 4 
HIV infection (irrespective of HCV infection and ARD status) had higher mortality rates than 5 
those without HIV infection (4.3 per 100 person-years vs. 1.9 per 100 person-years, p<0.0001) 6 
(see Table, Supplemental Digital Content 2).  7 
 8 
Among HIV+ patients, 57% initiated ART within one year of VACS enrollment (i.e., 9 
diagnosis of HIV within the VA), and an additional 21% had initiated ART during the study 10 
period. In 1997, 35% of HIV+ patients had CD4 <200 cells/mm3 and 20% had CD4 ³500 11 
cells/mm3. At the end of the study period, only 8% of HIV+ patients had CD4 <200 cells/mm3 12 
and 58% had CD4 ³500 cells/mm3. Among HCV+ patients, FIB-4 scores increased over the 13 
study period. At study start, 36% had FIB-4 scores between 1.45-3.25 and 16% had scores 14 
>3.25. By 2014, 51% had FIB-4 scores between 1.45-3.25 and 24% had scores >3.25. The 15 
majority (69%) of HCV-uninfected patients had FIB-4 scores <1.45 at study start and this 16 
remained stable over the entire study period.  17 
 18 
MICU admissions 19 
During follow-up, 29,887 (19%) patients were admitted to a MICU for a total of 56,805 20 
admissions; 61% had one admission, 33% had between two and four admissions, and 6% had 21 
five or more admissions. HCV+ patients experienced proportionately more MICU admissions 22 
than their HCV-uninfected counterparts in every HIV/ARD strata (42% of HCV+ had >1 23 
admission vs. 38% of HCV-uninfected, p<0.0001) (see Table, Supplemental Digital Content 3). 24 
The majority (63%) of MICU admissions occurred within the VA while the remaining 37% were 25 
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found in Medicare data (Table 2). The most common principal diagnoses for hospital stays with 1 
a MICU admission were CVD (28%), respiratory (14%), GI and liver (8%), neurologic (8%), 2 
severe sepsis or septic shock (6%), and other infections (6%).  3 
 4 
More HIV+/HCV+/ARD+ patients experienced MICU admission than HIV-/HCV-/ARD- 5 
patients (34% vs. 15%, p<0.0001) (see Table, Supplemental Digital Content 3). All HCV+ 6 
(irrespective of HIV infection and ARD status) were more likely than HCV-uninfected to have 7 
principal diagnoses related to GI and liver diseases, severe sepsis/septic shock, other 8 
infections, endocrine disorders, renal insufficiency, and alcohol- and drug use-related diagnoses 9 
(all p<0.0001). 10 
 11 
Trends in MICU admission rates 12 
Overall, annual MICU admission rates decreased by 37% from 37.5 admissions per 13 
1000 patients (37.5/1000) in 1997 to 23.7/1000 in 2014 (t-trend=-4.8, p<0.0001). The largest 14 
decrease was seen among HCV-uninfected patients, irrespective of HIV infection or ARD 15 
(Figure 1 with MICU admission rates decreasing by 48% over the study period from 34.0/1000 16 
in 1997 to 17.6/1000 in 2014 (t-trend=-17.2, p<0.0001). Among HCV+ patients there was no 17 
evidence of change in MICU admission rates from 1997 to 2014 (t-trend=+1.0, p=0.34). 18 
 19 
Relative risk for MICU admission 20 
There was minimal evidence of confounding by the adjusting covariates in each 21 
exposure group, with relative differences between crude and adjusted RR ranging from 4% to 22 
13% (Table 3). After adjusting for baseline age, baseline comorbidity, and calendar year, HIV 23 
infection and ARD were each associated with 46% increased risk of MICU admission compared 24 
to HIV-/HCV-/ARD- patients (RR 1.46, 95% CI 1.43-1.50 HIV infection; RR 1.46, 95% CI 1.42-25 
12 
 
1.50 ARD) (Table 3). HCV infection alone was associated with 33% greater risk compared to 1 
HIV-/HCV-/ARD- patients (RR 1.33, 95% CI 1.27-1.39). Models stratified by calendar period 2 
showed that HIV infection was more strongly associated with risk of MICU admission between 3 
1997-2009 (RR 1.61, 95% CI 1.56-1.65) than between 2010-2014 (RR 1.21, 95% CI 1.16-1.27). 4 
Conversely, HCV infection was more strongly associated with MICU admission in later years 5 
(RR 1.22, 95% CI 1.16-1.29 between 1997-2009; RR 1.54, 95% CI 1.43-1.67 between 2010-6 
2014). The association of ARD was similar in both time periods (RR 1.46, 95% CI 1.41-1.50 7 
between 1997-2009; RR 1.44, 95% CI 1.38-1.50 between 2010-2014). 8 
 9 
We found that the effect of ARD differed depending on the presence of other exposures. 10 
For example, ARD was associated with 33% (95% CI 1.28-1.38) increased risk of MICU 11 
admission among HIV+ patients and 47% (95% CI 1.42-1.52) increased risk among HIV-12 
uninfected patients (Table 3). Similar differential effects of ARD were observed between HCV+ 13 
and HCV-uninfected patients. Compared to patients with none of the exposures, those with all 14 
three had the highest risk of MICU admission (RR 2.36, 95% CI 2.26-2.46). 15 
 16 
Discussion 17 
Using a national cohort of 155,550 patients and combined data from the largest 18 
healthcare provider and insurer in the United States, we showed that HIV, HCV, and ARD were 19 
each independently associated with increased risk of MICU admission between 1997 and 2014. 20 
Compared to earlier years, risk of MICU admission in the last five years of follow-up decreased 21 
among HIV mono-infected patients but increased among HCV mono-infected patients. These 22 
findings illustrate that viral infections are associated with serious health conditions requiring 23 
MICU admission, but this association may be attenuated by effective treatments as 24 
demonstrated in HIV+ patients. Compared to HIV-/HCV-/ARD- patients, the contribution of ARD 25 
13 
 
to the risk of MICU admission remained consistent over the study period. Importantly, ARD 1 
accounts for 3.3 million deaths (5.9% of all deaths) each year worldwide11 and continues to be 2 
associated with substantial MICU admission risk, signifying the urgency to address this 3 
potentially modifiable health behavior. 4 
 5 
MICU admission rates decreased by 37% between 1997 and 2014. This differs from 6 
other national data that indicate increased MICU bed count and utilization over the past 15 7 
years in the United States.20 Decreasing MICU use in our study may be explained by several 8 
factors, including the fixed number of acute care VA facilities, changes to criteria for MICU 9 
admission, utilization of MICU resources, or expansion of step-down units. However, we 10 
included admissions reimbursed by Medicare, which would be expected to partially offset this 11 
effect. In addition, MICU admission rates in our study were substantially higher compared with 12 
prior studies of non-surgical ICU admission among the general VA patient population. 13 
Approximately 20% of participants in our cohort had at least one MICU admission during the 14 
observation period compared with 8% in a cross-sectional study between 2009-2010.21 This 15 
may be partially explained by differing study designs, including more HIV+ patients in the VACS 16 
cohort, who have higher MICU admission rates.  17 
 18 
MICU admission rates fell dramatically between 1997 and 2014 among patients without 19 
HCV infection, but were unchanged among patients with HCV infection, suggesting that HCV 20 
infection or associated risk factors played a role in MICU use during the study period. Without 21 
treatment, the adverse impact of HCV infection on MICU admissions could increase given the 22 
prevalence of HCV globally, estimated in 2015 at 1.0% of the general population (71.1 million 23 
infections),22 and the lag time between infection and development of HCV-related 24 
complications.23 We anticipate that the influence of HCV on MICU admission rates may change 25 
14 
 
after 2014 when modern direct-acting antivirals (DAA) for treatment of HCV infection became 1 
available to VA patients. These therapies are effective in achieving sustained virologic 2 
response,10 but whether this translates to improved clinical outcomes of conditions that 3 
commonly require MICU admission, such as sequelae of hepatic decompensation, remains to 4 
be seen. The importance of optimally deploying HCV treatments is highlighted by our study’s 5 
findings of the substantial impact of HCV infection on MICU admission through 2014. Future 6 
research should investigate the impact of DAA treatment on MICU admission rates among 7 
HCV+ patients with and without HIV co-infection. 8 
 9 
Our findings also highlight the importance of unhealthy alcohol use, a potentially 10 
modifiable health behavior, on MICU admission risk in patient populations with or without 11 
underlying HIV or HCV infection. In prior work, we showed that ARD are independently 12 
associated with all-cause hospitalization.4 Our current findings further underscore that patients 13 
with ARD also experience serious, potentially life-threatening complications that lead to MICU 14 
admission. Although the mechanism through which ARD influences MICU admission risk 15 
remains unclear, immune and neurocognitive impairments may play a role. In one study, alcohol 16 
dependence was independently associated with sepsis, septic shock, and hospital mortality 17 
among adult MICU patients.24 However, other studies suggest that MICU patients with ARD had 18 
similar25 or even lower mortality compared to those without ARD.26 Failure to detect harmful 19 
effects of ARD in MICU patients must be viewed with caution as these studies were limited by 20 
unbalanced comparator groups, with ARD groups being younger and with fewer comorbidities. It 21 
is critical to better understand the impact of ARD on important health outcomes such as MICU 22 
admission and determine how decreasing or eliminating alcohol use may offset these risks. We 23 
postulate that development and subsequent implementation of effective interventions targeting 24 
15 
 
unhealthy alcohol use could reduce MICU admission risk for broad populations of patients and 1 
decrease the morbidity and mortality of patients with ARD admitted to the MICU. 2 
 3 
Our study had limitations. First, our findings may reflect bias from admitting clinicians 4 
who have a lower threshold for admitting HCV+ patients to the MICU than other patient groups. 5 
Some HCV+ patients are at greater risk for infection and may have more significant 6 
derangements in biomarkers of infection such as lactate, a benchmark target for monitoring 7 
sepsis. Second, our analysis relied on ICD-9 codes for ARD to define alcohol exposure, which 8 
have low sensitivity for capturing true ARD status and therefore inflated MICU admission rates 9 
among those we classified as ARD-. Finally, nearly all individuals in VACS are men, which 10 
resembles the HIV population in many countries, but limits the ability to generalize our findings 11 
to other HIV cohorts with higher proportions of women. 12 
 13 
In summary, while MICU admission rates in this large, national cohort fell dramatically 14 
between 1997 and 2014 among patients without HCV, there was essentially no change in MICU 15 
admission rates among patients with HCV infection. While the additional risk of MICU admission 16 
conferred by HIV mono-infection decreased over time, both HCV infection and ARD remained 17 
major risk factors for MICU admission between 2010 and 2014. The impact of these conditions 18 
could substantially change with the combination of safe and effective treatment for HIV and 19 
HCV infections, and interventions targeting unhealthy alcohol use. 20 
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Table 1. Demographic and clinical characteristics 
among patients receiving care in the Veterans 
Aging Cohort Study between 1997 and 2014, 
n=155,550                                                                                                           
Characteristic n (%) 
Exposure group  
     HIV+ / ARD+ / HCV+ 5144 (3.3) 
     HIV+ / ARD+ / HCV- 9359 (6.0) 
     HIV+ / ARD- / HCV+ 4743 (3.1) 
     HIV+ / ARD- / HCV- 30534 (19.6) 
     HIV- / ARD+ / HCV+ 6682 (4.3) 
     HIV- / ARD+ / HCV- 25924 (16.7) 
     HIV- / ARD- / HCV+ 3653 (2.4) 
     HIV- / ARD- / HCV- 69511 (44.7) 
Age at baseline, median (IQR) 47 (40-54) 
Male sex 151,379 (97.3) 
Race/ethnicity  
     Black 73,221 (47.1) 
     White 62,084 (39.9) 
     Hispanic 12,761 (8.2) 
     Other or unknown 7,484 (4.8) 
Year of VACS enrollment  
     1997-2001 82,144 (52.8) 
     2002-2006 33,134 (21.3) 
     2007-2010 20,659 (13.3) 
     2011-2014 19,613 (12.6) 
Comorbidities at baseline  
     Psychiatric disorders 41,614 (26.8) 
     Hypertension 41,253 (26.5) 
     Drug use-related diagnoses 21,415 (13.8) 
     Diabetes 18,106 (11.6) 
     CVD 9,570 (6.2) 
     Anemia 8,369 (5.4) 
     COPD 7,043 (4.5) 
     Non-AIDS cancers 5,340 (3.4) 
     Renal insufficiency 3,764 (2.4) 
     Chronic hepatitis B 1,868 (1.2) 
     Liver diseases 1,560 (1.0) 
Mortality per 100 person-years 2.6 
Ever MICU admission 29,887 (19.2) 
Abbreviations: HIV - human immunodeficiency 
virus; VACS - Veterans Aging Cohort Study; HCV 
- hepatitis C virus; ARD - alcohol-related 
diagnosis; IQR - interquartile range; MICU - 
medical intensive care unit 
Note: ARD status was used as an ever/never 
measure in this table 
 
Table 2.  Characteristics of medical intensive care unit 
(MICU) admissions, n=56,805                                                                                                         
Characteristic n (%) 
Location  
     VA 35,883 (63.2) 
     Medicare 20,922 (36.8) 
LOS per admission in days, median (IQR) 6 (3-11) 
Primary admission diagnosis  
     CVD 16,151 (28.4) 
     Respiratory 7,682 (13.5) 
     GI and liver 4,770 (8.4) 
     Neurologic 4,374 (7.7) 
     Other infections 3,611 (6.4) 
     Severe sepsis/septic shock 3,469 (6.1) 
     Endocrine 3,248 (5.7) 
     HIV/AIDS 2,671 (4.7) 
     Renal insufficiency 2,224 (3.9) 
     Non-AIDS cancers 1,241 (2.2) 
     ARD 950 (1.7) 
     Psychiatric disorders 771 (1.4) 
     Drug use-related diagnoses 344 (0.6) 
     Other 5,299 (9.3) 
Abbreviations: IQR - interquartile range; HIV - human 
immunodeficiency virus; HCV - hepatitis C virus; ARD - 
alcohol-related diagnosis; MICU - medical intensive care 
unit; VA - Veterans Affairs; LOS - length of stay; CVD - 
cardiovascular disease; AIDS - acquired immune deficiency 
syndrome 
 
Table 3. Risk of medical intensive care unit (MICU) admission by HIV, hepatitis C virus (HCV), 
alcohol-related diagnosis (ARD), and calendar era, n=155,550 
All groups 
      Crude Adjusted Adjusted Adjusted 
Exposure group 1997-2014 1997-2014 1997-2009 2010-2014 
        
HIV+ 
ARD+ HCV+ 2.26 (1.17-2.34) 2.36 (2.26-2.46) 2.29 (2.17-2.42) 2.40 (2.23-2.58) HCV- 1.89 (1.83-1.95) 2.14 (2.06-2.22) 2.34 (2.24-2.44) 1.75 (1.64-1.86) 
        
ARD- HCV+ 1.64 (1.58-1.71) 1.74 (1.67-1.81) 1.66 (1.58-1.75) 1.94 (1.80-2.09) HCV- 1.38 (1.35-1.41) 1.46 (1.43-1.50) 1.61 (1.56-1.65) 1.21 (1.16-1.27) 
        
HIV- 
ARD+ HCV+ 1.72 (1.66-1.79) 1.80 (1.73-1.88) 1.69 (1.60-1.78) 1.91 (1.78-2.04) HCV- 1.37 (1.33-1.40) 1.46 (1.42-1.50) 1.46 (1.41-1.50) 1.44 (1.38-1.50) 
        
ARD- HCV+ 1.25 (1.20-1.31) 1.33 (1.27-1.39) 1.22 (1.16-1.29) 1.54 (1.43-1.67) HCV- ref ref ref ref 
              
By HIV 
        
HIV+ 
HCV+/ARD+ 1.64 (1.57-1.70) 1.62 (1.55-1.70) 1.45 (1.37-1.53) 1.98 (1.83-2.14) 
HCV+/ARD- 1.19 (1.14-1.24) 1.19 (1.14-1.24) 1.04 (0.99-1.09) 1.60 (1.48-1.73) 
HCV-/ARD+ 1.37 (1.32-1.42) 1.33 (1.28-1.38) 1.33 (1.28-1.39) 1.29 (1.21-1.38) 
HCV-/ARD- ref ref ref ref 
HIV- 
HCV+/ARD+ 1.72 (1.66-1.79) 1.76 (1.69-1.84) 1.65 (1.56-1.74) 1.88 (1.75-2.02) 
HCV+/ARD- 1.25 (1.20-1.31) 1.29 (1.23-1.35) 1.19 (1.12-1.26) 1.52 (1.41-1.65) 
HCV-/ARD+ 1.37 (1.33-1.41) 1.47 (1.42-1.52) 1.49 (1.43-1.55) 1.36 (1.29-1.44) 
HCV-/ARD- ref ref ref ref 
              
By HCV 
        
HCV+ 
HIV+/ARD+ 1.80 (1.69-1.92) 1.78 (1.66-1.90) 1.88 (1.73-2.04) 1.55 (1.39-1.74) 
HIV+/ARD- 1.31 (1.26-1.37) 1.31 (1.25-1.37) 1.36 (1.29-1.43) 1.26 (1.17-1.35) 
HIV-/ARD+ 1.37 (1.32-1.43) 1.36 (1.30-1.42) 1.38 (1.31-1.46) 1.24 (1.14-1.34) 
HIV-/ARD- ref ref ref ref 
HCV- 
HIV+/ARD+ 1.89 (1.83-1.95) 2.14 (2.06-2.22) 2.34 (2.24-2.44) 1.75 (1.64-1.86) 
HIV+/ARD- 1.38 (1.35-1.41) 1.46 (1.43-1.50) 1.60 (1.56-1.65) 1.21 (1.16-1.27) 
HIV-/ARD+ 1.37 (1.33-1.40) 1.46 (1.42-1.50) 1.46 (1.41-1.50) 1.44 (1.38-1.50) 
HIV-/ARD- ref ref ref ref 
              
Notes: reported as RR (95% confidence intervals); models adjusted for baseline age, comorbidity 
(psychiatric disorders, hypertension, drug use-related diagnoses, diabetes, cardiovascular disease, 
anemia, chronic obstructive pulmonary disorder, non-AIDS cancers, renal insufficiency, chronic 
hepatitis B, and liver diseases), and calendar year 
Abbreviations: HIV - human immunodeficiency virus; RR - rate ratio; CI - confidence interval; ref - 
referent group 
 
Figure 1. Age-adjusted medical intensive care unit admission rates per 1000 at-risk patients enrolled in the Veterans Aging Cohort Study 
between 1997 and 2014, by HIV, hepatitis C virus (HCV), and time-updated alcohol-related diagnosis (ARD)
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Supplemental Table 1. Categorization of ICD-9 codes for principal admission diagnoses and comorbidities                                                                                                              
Category ICD-9 codes 
Alcohol-related 
diagnoses 
291.X; 303.X; 305-305.03; 357.5; 425.5; 535.3; 571-571.3; 790.3; 980, 980.8-980.9; 
E860.0/.1/.8/.9; V11.3 
Anemia 280-281.9; 282.1/.2/.3/.4/.5/.6X/.7/.8/.9; 283.X; 284/.8/.9; 285/.2X/.8/.9 
Cardiovascular disease 
401.X; 402.01-.91; 404-404.11; 404.13/.91/.93; 410-414.07; 414.8/.9; 423-428.9; 
429.7; 433-437.1; 437.6-438.12; 438.2-.53; 438.81-.82; 438.89-441.9; 
443/.1/.8X/.9; 447.1; 557.X; 780.2; 785.1-785.4; 786.5X; 996-996.1; 996.71/.72; 
V43.4; V45.81/.82 
Chronic hepatitis B 070.2-070.33; 070.42/.52; V02.61 
COPD 490/491.1/.2/.21/.8/.9; 492.X; 496 
Diabetes 250-250.93; 357.2 
Drug use-related 
diagnoses 292.X; 304-305.93 
Endocrine 240-279.99 
GI and liver 280.X; 520-579.99; 787.X; 789-789.09; V55.3 
HIV/AIDS 042-044; 176.X; 200-202.98; V08 
Hypertension 401-405.99; 437.2 
Liver diseases 070; 070.2X/.44/.6; 456-456.2; 570; 571.2/.5/.6; 572.2/.3/.4/.8; 789.5 
Psychiatric disorders 293-301.9; 309.X; 311; V11 
Neurologic 290.4; 320-389.99; 430-459.99; 721.3; 722.X; 723.0/.4; 724.0X/.2/.4; 780.0X/.3X/.4/.97; 781.2/.3; 784; 852.2 
Non-AIDS cancers 140-175.9; 179-199.2; 201.X; 202.3-.68; 203-208.92 (excluding remission codes); V58.0; V58.1; V58.11 
Other infections 001-139.99 (excluding 042-044); 421.0; 424.90; 599.0; 604.X; 681-682.9; 711.0X; 730.X; 780.6; 790.7; 995.91-995.94; 996.6X; 997.62; 998.5X; 999.3X 
Renal insufficiency 285.21; 403.01/.11/.90/.91; 404.02/.03/.12/.13/.92/.93; 580-594.9; 596.X; 599.7; 600.0X; 788.2; 792.5; 996.3X; 996.73; 996.81; 997.5; V42; V45.1; V56.X 
Respiratory 415-416.9; 460-519.99; 780.57; 786.0X/.2/.52 
Severe sepsis/septic 
shock 
020.0; 038; 096.7; 112.5/.81; 286.6/.9; 287.4/.5; 293.0; 343.3; 348.1; 458.0; 570.0; 
573.4; 584.0; 785.50/.52; 995.92 
Abbreviations: ICD-9 - The International Classification of Diseases, Ninth Revision; COPD - chronic obstructive 
pulmonary disorder; GI - gastrointestinal; HIV - human immunodeficiency virus; AIDS - acquired immune 
deficiency syndrome 
 
Supplemental Table 2. Demographic and clinical characteristics by HIV, hepatitis C virus (HCV) infection, and alcohol-related diagnosis (ARD) among 
patients receiving care in the Veterans Aging Cohort Study between 1997 and 2014, n=155,550                                                                                                           
 HIV+/ARD+ HIV+/ARD- HIV-/ARD+ HIV-/ARD- 
 HCV+ HCV- HCV+ HCV- HCV+ HCV- HCV+ HCV- 
Characteristic (n=5,144) (n=9,359) (n=4,743) (n=30,534) (n=6,682) (n=25,924) (n=3,653) (n=69,511) 
Age at baseline, median (IQR) 47 (42-51) 45 (39-51) 49 (44-54) 47 (39-55) 47 (43-52) 46 (40-52) 49 (45-54) 48 (40-56) 
Male sex 5,050 (98.2) 9,086 (97.1) 4,671 (98.5) 29,713 (97.3) 6,626 (99.2) 25,545 (98.5) 3,597 (98.5) 67,091 (96.5) 
Race/ethnicity         
     Black 3,358 (65.3) 5,271 (56.3) 2,546 (53.7) 12,711 (41.6) 4,122 (61.7) 13,864 (53.5) 2,069 (56.6) 29,280 (42.1) 
     White 1,299 (25.3) 3,186 (34.0) 1,487 (31.4) 13,588 (44.5) 1,999 (29.9) 9,461 (36.5) 1,162 (31.8) 29,902 (43.0) 
     Hispanic 412 (8.0) 644 (6.9) 541 (11.4) 2,361 (7.7) 493 (7.4) 2,028 (7.8) 340 (9.3) 5,942 (8.6) 
     Other or unknown 75 (1.5) 258 (2.8) 169 (3.6) 1,874 (6.1) 68 (1.0) 571 (2.2) 82 (2.2) 4,387 (6.3) 
Year of VACS enrollment         
     1997-2001 3,407 (66.2) 5,355 (57.2) 2,709 (57.1) 15,078 (49.4) 4,251 (63.6) 15,271 (58.9) 2,054 (56.2) 34,019 (48.9) 
     2002-2006 1,040 (20.2) 1,916 (20.5) 1,040 (21.9) 6,125 (20.1) 1,388 (20.8) 5,011 (19.3) 801 (21.9) 15,813 (22.8) 
     2007-2010 464 (9.0) 1,272 (13.6) 511 (10.8) 4,395 (14.4) 576 (8.6) 2,994 (11.6) 467 (12.8) 9,980 (14.4) 
     2011-2014 233 (4.5) 816 (8.7) 483 (10.2) 4,936 (16.2) 467 (7.0) 2,648 (10.2) 331 (9.1) 9,699 (14.0) 
Comorbidities at baseline, frequency        
     None 1,358 (26.4) 2,841 (30.4) 2,221 (46.8) 15,438 (50.6) 1,856 (27.8) 8,099 (31.2) 1,383 (37.9) 32,733 (47.1) 
     One 1,386 (26.9) 2,696 (28.8) 1,297 (27.4) 8,286 (27.1) 1,929 (28.9) 8,394 (32.4) 1,094 (30.0) 20,529 (29.5) 
     Two or more 2,400 (46.7) 3,822 (40.8) 1,225 (25.8) 6,810 (22.3) 2,897 (43.4) 9,431 (36.4) 1,176 (32.2) 16,249 (23.4) 
Comorbidities at baseline, by type         
     Psychiatric disorders 2,069 (40.2) 3,762 (40.2) 1,005 (21.2) 6,344 (20.8) 2,696 (40.4) 10,350 (39.9) 995 (27.2) 14,393 (20.7) 
     Hypertension 1,123 (21.8) 1,936 (20.7) 1,029 (21.7) 5,908 (19.4) 1,829 (27.4) 7,127 (27.5) 1,205 (33.0) 21,096 (30.4) 
     Drug use-related diagnoses 2,754 (53.5) 3,605 (38.5) 698 (14.7) 1,733 (5.7) 3,053 (45.7) 7,463 (28.8) 443 (12.1) 1,666 (2.4) 
     Diabetes 434 (8.4) 558 (6.0) 453 (9.6) 2,491 (8.2) 755 (11.3) 2,430 (9.4) 625 (17.1) 10,360 (14.9) 
     CVD 205 (4.0) 482 (5.2) 229 (4.8) 1,692 (5.5) 267 (4.0) 1,348 (5.2) 225 (6.2) 5,122 (7.4) 
     Anemia 431 (8.4) 942 (10.1) 436 (9.2) 3,237 (10.6) 219 (3.3) 943 (3.6) 139 (3.8) 2,022 (2.9) 
     COPD 297 (5.8) 651 (7.0) 199 (4.2) 1,270 (4.2) 338 (5.1) 1,428 (5.5) 148 (4.1) 2,712 (3.9) 
     Non-AIDS cancers 117 (2.3) 262 (2.8) 145 (3.1) 1,332 (4.4) 158 (2.4) 615 (2.4) 111 (3.0) 2,600 (3.7) 
     Renal insufficiency 154 (3.0) 314 (3.4) 243 (5.1) 1.292 (4.2) 114 (1.7) 301 (1.2) 121 (3.3) 1,225 (1.8) 
     Chronic hepatitis B 221 (4.3) 336 (3.6) 153 (3.2) 746 (2.4) 134 (2.0) 139 (0.5) 34 (0.9) 105 (0.2) 
     Liver diseases 160 (3.1) 215 (2.3) 128 (2.7) 296 (1.0) 175 (2.6) 341 (1.3) 93 (2.6) 152 (0.2) 
Mortality per 100 person-years 3.8 3.9 4.5 4.6 2.3 1.9 2.4 1.9 
Ever MICU admission 1,736 (33.8) 2,445 (26.1) 1,369 (28.9) 6,117 (20.0) 1,811 (27.1) 5,097 (19.7) 797 (21.8) 10,515 (15.1) 
Abbreviations: HIV - human immunodeficiency virus; VACS - Veterans Aging Cohort Study; HCV - hepatitis C virus; ARD - alcohol-related diagnosis; IQR - 
interquartile range; MICU - medical intensive care unit 
Note: ARD status was used as an ever/never measure in this table; all comparisons across exposure groups p<0.0001 using non-parametric Kruskal-Wallis 
test for continuous measures and chi-square tests for categorical measures 
 
Supplemental Table 3.  Characteristics of medical intensive care unit (MICU) patients by HIV, hepatitis C virus (HCV) infection, and alcohol-related diagnosis 
(ARD), n=29,887                                                                                                         
 HIV+/ARD+ HIV+/ARD- HIV-/ARD+ HIV-/ARD- 
 HCV+ HCV- HCV+ HCV- HCV+ HCV- HCV+ HCV- 
  (n=1,736) (n=2,445) (n=1,369) (n=6,117) (n=1,811) (n=5,097) (n=797) (n=10,515) 
Admitted patients, median (IQR)         
     Years to first MICU admission 6 (3-10) 4 (2-8) 6 (2-10) 4 (1-7) 6 (3-11) 6 (3-10) 7 (3-11) 6 (2-10) 
     Number of MICU admissions         
          1 admission 981 (56.5) 1,525 (62.4) 844 (61.7) 4,146 (67.8) 1,021 (56.4) 3,038 (59.6) 457 (57.3) 6,192 (58.9) 
          2-4 admissions 632 (36.4) 784 (32.1) 455 (33.2) 1,715 (28.0) 644 (35.6) 1,690 (33.2) 273 (34.3) 3,612 (34.4) 
          ≥5 admissions 123 (7.1) 136 (5.6) 70 (5.1) 256 (4.2) 146 (8.1) 369 (7.2) 67 (8.4) 711 (6.8) 
 HIV+/ARD+ HIV+/ARD- HIV-/ARD+ HIV-/ARD- 
 HCV+ HCV- HCV+ HCV- HCV+ HCV- HCV+ HCV- 
  (n=3,495) (n=4,478) (n=2,470) (n=10,195) (n=3,746) (n=10,211) (n=1,612) (n=20,598) 
Admissions (n=56,805)         
     Location         
          VA 2,591 (74.1) 3,138 (70.1) 1,711 (69.3) 6,494 (63.7) 2,820 (75.3) 7,263 (71.1) 1,015 (63.0) 10,851 (52.7) 
          Medicare 904 (25.9) 1,340 (29.9) 759 (30.7) 3,701 (36.3) 926 (24.7) 2,948 (28.9) 597 (37.0) 9,747 (47.3) 
     LOS per admission, days 6 (3-13) 6 (3-13) 7 (3-13) 6 (3-13) 5 (2-11) 5 (2-10) 5 (3-11) 5 (3-10) 
     Primary admission diagnosis         
          CVD 556 (15.9) 839 (18.7) 435 (17.6) 2,384 (23.4) 830 (22.2) 2,919 (28.6) 462 (28.7) 7,726 (37.5) 
          Respiratory 454 (13.0) 648 (14.5) 335 (13.6) 1,341 (13.2) 374 (10.0) 1,472 (14.4) 193 (12.0) 2,865 (13.9) 
          GI and liver 362 (10.4) 345 (7.7) 219 (8.9) 723 (7.1) 522 (13.9) 1,074 (10.5) 144 (8.9) 1,381 (6.7) 
          Neurologic 232 (6.6) 315 (7.0) 172 (7.0) 700 (6.9) 271 (7.2) 775 (7.6) 132 (8.2) 1,777 (8.6) 
          Other infections 243 (7.0) 279 (6.2) 215 (8.7) 845 (8.3) 222 (5.9) 396 (3.9) 137 (8.5) 1,274 (6.2) 
          Severe sepsis/septic shock 251 (7.2) 285 (6.4) 238 (9.6) 737 (7.2) 200 (5.3) 426 (3.2) 115 (7.1) 1,217 (5.9) 
          Endocrine 203 (5.8) 193 (4.3) 127 (5.1) 393 (3.9) 297 (7.9) 729 (7.1) 108 (6.7) 1,198 (5.8) 
          HIV/AIDS 284 (8.1) 519 (11.6) 274 (11.1) 1,594 (15.6) - - - - 
          Renal insufficiency 173 (5.0) 177 (4.0) 153 (6.2) 442 (4.3) 145 (3.9) 286 (2.8) 95 (5.9) 753 (3.7) 
          Non-AIDS cancers 54 (1.6) 69 (1.5) 49 (2.0) 208 (2.0) 82 (2.2) 184 (1.8) 34 (2.1) 561 (2.7) 
          ARD 57 (1.6) 51 (1.1) 11 (0.5) 20 (0.2) 64 (1.7) 105 (1.0) 10 (0.6) 26 (0.1) 
          Psychiatric disorders 84 (2.4) 110 (2.5) 12 (0.5) 54 (0.5) 92 (2.5) 233 (2.3) 13 (0.8) 173 (0.8) 
          Drug use-related diagnoses 57 (1.6) 51 (1.1) 11(0.5) 20 (0.2) 64 (1.7) 105 (1.0) 10 (0.6) 26 (0.1) 
          Other 431 (12.3) 519 (11.6) 228 (9.2) 745 (7.3) 457 (12.2) 1,121 (11.0) 167 (10.4) 1,631 (7.9) 
Abbreviations: HIV - human immunodeficiency virus; HCV - hepatitis C virus; ARD - alcohol-related diagnosis; MICU - medical intensive care unit; IQR - 
interquartile range; VA - Veterans Affairs; LOS - length of stay; CVD - cardiovascular disease; AIDS - acquired immune deficiency syndrome 
Notes: ARD status was used as an ever/never measure in this table; all comparisons across exposure groups p<0.0001 using non-parametric Kruskal-Wallis 
test for continuous measures and chi-square tests for categorical measures 
 
